Interventional Cardiology

The public health department's crucial decision to negotiate with leading firms to halve the price of drug-eluting stents has helped well over 100 poor patients in just a fortnight.

The US Coronary Stent Industry Outlook to 2018 – Bioabsorbable Stents to Drive the Future Growth” provides a comprehensive analysis of the various aspects such as the market size of the US Coronary Stent industry, market segments i.e. drug eluting and bare metal stents and future outlook of the industry. The report also covers the market share of major players in the US.

Hurley Medical Center is the only medical center in Genesee County and one of six in the state to use a new kind of drug-coated stent, the Zilver PTX drug-eluting peripheral stent designed to treat peripheral artery disease.

Alternatives means of delivering drugs such as paclitaxel could have a similar effect to drug-eluting stents without the invasive procedure, according to a new study to be published in the journal Nanomedicine: Nanotechnology, Biology and Medicine.

SANTA ROSA -- Medtronic, Inc. (NYSE: MDT) on Tuesday reported its Cardiac and Vascular group, which is based in Santa Rosa, reported global sales of $2.119 billion, an increase of 1 percent over the year.
The Minneapolis-based company as a whole, however, reported that its third quarter net profit dropped 23 percent, largely related to the discontinuation of a high blood pressure treatment that failed to make it out of trial.

Interruption of dual antiplatelet therapy (DAPT) in patients with second-generation zotarolimus-eluting stents (ZES) is unlikely to lead to stent thrombosis as long as it occurs at least 1 month after implantation, according to a retrospective study published online February 7, 2014, ahead of print in the European Heart Journal. However, earlier interruption is associated with a high risk of adverse events.

Primary Percutaneous Coronary Intervention (PCI) has made huge leaps of improvement in the last two decades, with the ever goal being permanent sufficient flow in the coronary artery. From balloon angioplasty alone to subsequent Bare Metal Stent (BMS) implantation, measures have been made to achieve this aim. The introduction of the Drug Eluting Stent (DES) proved an ever better outcome: the antiproliferative drug coated struts seemed to cause an end to the last barrier of coronary reclosure: neo-intimal hyperproliferation inside the stent. However, contradicting results with regard to stent safety and effectiveness have been published and therefore we sought to compare the BMS with the DES in a real world STEMI-registry. Primarily, we aimed to investigate the DES ability in preventing target lesion revascularizations (TLR) as a result of in-stent restenosis. Our secondary endpoint was to compare both safety and effectiveness of both stent types.